Bayer’s Rally Hits a Technical Speed Bump as the Supreme Court Weighs a Game-Changing Glyphosate Ruling
Published on 07/22/2026 at 21:03 | Redaktion boerse-global.de
Bayer’s stock has been on a tear, but the past few days have delivered a mixed bag of technical signals and legal developments that leave investors parsing short-term noise against a potentially transformative legal backdrop. The shares slipped 1.76 percent on Wednesday to €46.76, breaking below the 20-day moving average for the first time in weeks — a short-term trendline that had been pointing firmly upward since mid-June.
The pullback follows a blistering run. Since Bayer entered a formal long-term uptrend on June 17, 2026, the stock has surged 30.56 percent. Over the past 30 days alone, it added 23.02 percent. On a 12-month basis, the gain stands at a staggering 68.17 percent. With that kind of momentum, a breather was almost inevitable. The current price sits 13.18 percent below the 2026 high of €53.86 touched on July 3, but still a towering 86.33 percent above the 52-week low of €25.09 from August 2025.
Despite the dip, the medium-term technical picture remains robust. The 50-day moving average at €41.81 sits 11.84 percent below the current price, while the 200-day average at €38.51 is 21.43 percent lower. The 14-day relative strength index at 52.8 points to a neutral market — neither overbought nor oversold — suggesting room to move in either direction. What stands out is the volatility: the annualized 30-day figure clocks in at 62.90 percent, unusually high for a DAX constituent of Bayer’s size, reflecting the persistent uncertainty around legal risks and the balance sheet structure of its agricultural business.
Should investors sell immediately? Or is it worth buying Bayer?
That legal uncertainty took center stage on two fronts this week. On July 21, Bayer’s Monsanto subsidiary withdrew its petition for anti-dumping duties on glyphosate imports from China. The company had originally sought tariffs ranging from 68.9 percent to a staggering 446.47 percent. After pushback from U.S. farm groups — including the National Corn Growers Association, the American Soybean Association, and the National Association of Wheat Growers — Bayer backed down. The subsidiary Ruveon said it would maintain its market-oriented dynamic pricing. The farm groups welcomed the retreat, which defuses a conflict that had put Bayer in an awkward spot between its own trade interests and its agricultural customers.
Far more consequential for the long-term risk profile is the case before the U.S. Supreme Court. The justices are weighing whether federal law preempts state-level lawsuits against Bayer over the Roundup herbicide. Bayer argues it should. The outcome will directly determine the scale of future damages from the thousands of pending glyphosate-related claims. The hearing comes with political heat: activists from the “MAHA moms” movement are protesting and threatening electoral consequences in the upcoming midterm elections if the court rules in Bayer’s favor. U.S. Health Secretary Robert F. Kennedy Jr. has publicly stated that glyphosate causes cancer, adding to the political temperature. The case gains further significance from an EPA review of the active ingredient scheduled for October 2026, which could shift the legal landscape again.
The market’s reaction to this news flow has been measured. At €47.78, the stock has gained 29.10 percent year-to-date and sits just 11.29 percent below its July high. That suggests investors are pricing in hope that the Supreme Court could deliver a preemption ruling that caps the legal exposure, rather than treating the ongoing litigation as an immediate drag. For now, the tariff retreat removes a short-term irritant, while the Supreme Court decision looms as the defining catalyst for the next leg of Bayer’s recovery story.
Ad
Bayer Stock: New Analysis - 22 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
